Brain arrest: the neurological determination of death and organ donor management in Canada
Severe brain injury to neurological determination of death: Canadian forum recommendations

Sam D. Shemie, Christopher Doig, Bernard Dickens, Paul Byrne, Brian Wheelock, Graeme Rocker, Andrew Baker, T. Peter Seland, Cameron Guest, Dan Cass, Rosella Jefferson, Kimberly Young, Jeanne Teitelbaum, on behalf of the Pediatric Reference Group and the Neonatal Reference Group

The management of patients with severe brain injury falls within the disciplines of emergency medical services, trauma, critical care, neurology and neurosurgery. Consultation and collaboration between professionals in these disciplines and those involved in end-of-life care and organ donation and transplantation are required to standardize and optimize the management of severely brain-injured patients who progress to neurological death.

Brain death is better understood as brain arrest, or the final clinical expression of complete and irreversible neurological failure. Despite widespread national, international and legal acceptance of the concept of death as defined by neurological criteria, substantial variation exists in the standards and their application.1–5 In all Canadian provinces and territories, the legal definition of brain death is “according to accepted medical practice.” These practices are largely determined by individual hospitals or regions. Guidelines established by the Canadian Congress Committee on Brain Death in 19886 and the Canadian Neurocritical Care Group in 1997 initiated clarification of the criteria, but have not led to uniform practice.

Acknowledging this variation in the recognition, diagnosis and documentation of neurological death, the Canadian Council for Donation and Transplantation sponsored a national forum of experts to create a set of recommendations that will have significant implications for organ donation in Canada. Severe brain injury is a prerequisite for neurological determination of death (NDD); and NDD, commonly referred to as brain death, is a prerequisite for cadaveric organ donation. The right to entertain the option of organ and tissue donation is increasingly supported by society and will become legislated in some Canadian jurisdictions. Collaborative efforts are required to optimize the care of patients who may become eligible for donation and to ensure consistent and ethical conduct in care. This comprehensive national collaboration is the first of its kind in Canada in this domain.

Forum overview

The purpose of the forum “Severe Brain Injury to Neurological Determination of Death,” held in Vancouver from 9 to 11 April 2003, was to initiate the development of a national agreement on the processes of care, commencing with severe brain injury and culminating with NDD. A priori, the forum accepted brain death as a medical and legal concept of death in Canadian society and restricted the discussion to optimum practice in the field. Objectives were

• To review national and international legislation, policies and practices related to NDD
• To prepare a made-in-Canada definition of NDD for children and adults, to ensure consistency and reliability in its diagnosis, declaration, documentation and reporting
• To discuss and agree on policies and practices in relation to emergency department, neurological, neurosurgical and intensive care unit (ICU) management of critically injured patients with a poor neurological prognosis
• To develop recommendations for the Canadian Council for Donation and Transplantation and other interested organizations and groups on the dissemination of these definitions, policies and practices across Canada.

The forum was attended by 89 experts, including emergency, trauma and critical care physicians, neurologists, neurosurgeons, nurses and advanced nurse practitioners, as well as representatives of licensing colleges and donation—transplant agencies, health administrators, policy-makers, coroners, experts in end-of-life care and ethicists—a multidisciplinary group representing all regions of the country. Discussions focused on collaboration at a national level.

Each of the 3 main areas of focus — recommendations for a Canadian definition, criteria and minimum testing requirements for NDD; recommendations concerning the incidence and reporting of NDD and legal issues; and recommendations associated with the management of patients with severe brain injury from the emergency department to the intensive care unit — was addressed using the following process. Presentations by experts were followed by plenary discussions supported by fact sheets that summarized preceding American7 and Canadian guidelines8 and by substantial background papers9–11 and surveys12 provided by the planning committee in advance of the forum. Small-group discussions then focused on specific questions related to the processes of care. The Forum Recommendations Group (FRG) and the Pediatric Reference Group (PRG) reviewed the results of the small-group discussions, developed unanimous recommendations for adults and children and returned these for plenary discussion. A Neonatal Reference Group met subsequent to the forum to develop neonatal age-adjusted recommendations. (See Appendix 1 for a list of...
members of these groups.) Clinical checklists are included in Appendix 4.

Discussions at the forum were intense, rich in content and collegial. Members of the FRG and PRG panels unanimously agreed on recommendations that mark a significant advance on existing guidelines. Group members were invited to sit on these panels, both as representatives of their professional associations and as respected practitioners providing the benefit of their experience and expertise. Both panels were assisted by an external, objective facilitator.

Forum recommendations were developed for infants, children, adolescents and adults. Drs. Paul Byrne and Sam Shemie were members of both the FRG and PRG and provided consistent pediatric input during the development of guidelines in plenary sessions and at FRG and PRG meetings.

General considerations

During discussions, FRG and PRG members recognized that

- Recommendations must be in the best interests of patients with severe brain injury.
- Optimum end-of-life care is a priority for all patients who may die after severe brain injuries.
- The wishes of patients and their families are of paramount importance.
- There is a need to clarify and standardize terminology, e.g., ancillary and supplementary testing, brain death (NDD, neurologically determined death or death by neurological determination [see Appendices 2 and 3]).
- The current evidence base for existing NDD guidelines is inadequate.
- Clear medical standards for NDD and defining qualifications of physicians performing NDD augment the quality and rigour of the determination.

Overarching recommendations

In discussions related to Recommendations A.4: Apnea testing, A.5: Examination interval and A.7: Concept and definition of neurological death, FRG members identified the following overarching recommendations, which apply to all of the individual recommendations:

- We recommend that after NDD, the patient be declared dead.
- Existing provincial and territorial laws indicate that for the purposes of a post-mortem transplant, the fact of death shall be determined by at least 2 physicians in accordance with accepted medical practice. There is no clear medical basis for the law requiring a second physician to determine death before post-mortem transplantation.
- The first and second physicians’ determinations, required by law, may be performed concurrently. However, if the determinations are performed at different times, a full clinical examination, including apnea testing, must be performed at each determination. No fixed interval of time is recommended for the second determination, except where age-related criteria apply.

A. Canadian medical standards for NDD: definition, criteria and minimum testing

Recommendation A.1: Minimum clinical criteria for NDD

We recommend use of the following minimum clinical criteria as a Canadian medical standard for NDD:

- Established etiology capable of causing neurological death in the absence of reversible conditions capable of mimicking neurological death
- Deep unresponsive coma with bilateral absence of motor responses, excluding spinal reflexes
- Absent brain stem reflexes as defined by absent gag and cough reflexes and the bilateral absence of
  - corneal responses
  - pupillary responses to light, with pupils at mid-size or greater
  - vestibulo-ocular responses
- Absent respiratory effort based on the apnea test
- Absent confounding factors

Key considerations

- A prerequisite for NDD is the absence of clinical neurological function with a known, proximate cause that is irreversible. There must be definite clinical or neuro-imaging evidence of an acute central nervous system (CNS) event consistent with the irreversible loss of neurological function.
- Deep unresponsive coma implies a lack of spontaneous movements as well as an absence of movement originating in the CNS, such as cranial nerve function, CNS-mediated motor response to pain in any distribution, seizures, decorticate and decerebrate responses. Spinal reflexes or motor responses confined to spinal distribution may persist.
- Minimum should not necessarily be understood as minimal. “Minimal” refers to the least possible that can be done and is an absolute value. “Minimum” refers to the lowest acceptable standard, which is a relative standard, often pitched above the minimal. The standard recommended by the forum sets minimum clinical criteria for NDD.

Recommendation A.2: Confounding factors

We recommend that, at the time of assessment for NDD, the following confounding factors preclude the clinical diagnosis:

- Unresuscitated shock
- Hypothermia (core temperature < 34°C)
- Severe metabolic disorders capable of causing a potentially reversible coma
- Severe metabolic abnormalities, including glucose, electrolytes (including phosphate, calcium and magnesium), inborn errors of metabolism, and liver and renal dysfunction may play a role in clinical presentation. If the primary etiology does not fully explain the clinical picture, and if in the treating physician’s judgement the metabolic abnormality may play a role, it should be corrected.
- Peripheral nerve or muscle dysfunction or neuromuscular...
blockade potentially accounting for unresponsiveness

- Clinically significant drug intoxications (e.g., alcohol, barbiturates, sedatives, hypnotics); however, therapeutic levels or therapeutic dosing of anticonvulsants, sedatives and analgesics do not preclude the diagnosis.

**Key considerations**

- Neurological assessments may be unreliable in the acute post-resuscitation phase after cardiorespiratory arrest. In cases of acute hypoxic-ischemic brain injury, clinical evaluation for NDD should be delayed for 24 h subsequent to the cardiorespiratory arrest or an ancillary test could be performed (see Recommendation A.6).
- It is recognized that there are variations in confounding factors that may be associated with NDD; examiners are cautioned to review these confounding factors in the context of the primary etiology and examination. If physicians are confounded by data, either absolutely or by differing perspectives, they should not proceed with NDD. Clinical judgment is the deciding factor.

**Recommendation A.3: Minimum temperature**

The core body temperature required to apply the minimum clinical criteria (Recommendation A.1) should be ≥ 34°C.

**Key considerations**

- Core temperature should be obtained through central blood, rectal or esophageal–gastric measurement.
- The existing Canadian standard of 32.2°C was based on precedent. The relevance of the scientific evidence and the application of this standard in the context of severe brain injury is uncertain.
- Given that there is no evidence base, a decision was made to adopt 34°C as a rational, safe and attainable standard. This decision was based on the following rationale:
  - Ideally, temperature should be as close to normal as possible and this is the minimum temperature at which the test is valid.
  - Raising a patient’s temperature from 32.2°C to 34°C does not pose significant difficulty to the patient or treating physician.

**Recommendation A.4: Apnea testing**

We recommend that the thresholds at the completion of the apnea test be PaCO₂ ≥ 60 mm Hg (and ≥ 20 mm Hg above the pre-apnea test level) and pH ≤ 7.28. These thresholds must be documented by arterial blood gas measurement.

To interpret an apnea test correctly, the certifying physician must continuously observe the patient for respiratory effort throughout the administration of the test.

**Key considerations**

- Optimum administration of the apnea test requires a period of preoxygenation followed by 100% oxygen delivered via the trachea upon disconnection from mechanical ventilation.

- The following codicil is required to address severe lung disease: Caution must be exercised in considering the validity of the apnea test if, in the physician’s judgment, there is a history suggestive of chronic respiratory insufficiency and responsiveness to only supranormal levels of carbon dioxide, or if the patient is dependent on hypoxic drive. If the physician cannot be sure of the validity of the apnea test, an ancillary test should be administered.

**Recommendation A.5: Examination interval**

We recommend that when a second determination is performed, there should be no fixed examination interval, regardless of the primary mechanism of the brain injury.

**Recommendation A.6: Ancillary tests**

We recommend that an ancillary test be performed when it is impossible to complete the minimum clinical criteria as defined in Recommendation A.1. At a minimum, 2 particular clinical criteria must be met before ancillary tests are performed:

- An established etiology capable of causing neurological death in the absence of reversible conditions capable of mimicking neurological death.
- Deep unresponsive coma.

We recommend that demonstration of the global absence of intracerebral blood flow be considered as the standard for NDD by ancillary testing.

**Key considerations**

- Before performing an ancillary test, unresuscitated shock and hypothermia must be corrected (see Recommendation A.2).
- The term “ancillary” should be understood to mean an alternative test to one that otherwise, for any reason, cannot be conducted. It replaces previous terminology such as “supplemental” (in addition to an already conducted test) or “confirmatory” (confirms a previously conducted test).
- Existing evidence, although not firmly established, suggests that for patients who fulfill minimum clinical criteria (see Recommendation A.1) under the circumstances of high-dose barbiturate therapy used for refractory intracranial hypertension to achieve deep coma or electrocerebral silence, NDD can be confirmed by the demonstration of absence of intracerebral blood flow.
- A description of ancillary testing is provided in Appendix 3.

**Recommendation A.7: Concept and definition of neurological death**

We recommend that neurologically determined death be defined as the irreversible loss of the capacity for consciousness combined with the irreversible loss of all brain stem functions (as defined in Recommendation A.1), including the capacity to breathe.

**Key consideration**

Death determined by neurological criteria may occur as a con-
sequence of intracranial hypertension or primary direct brain stem injury or both. In instances of intracranial hypertension, ancillary testing demonstrating absence of intracerebral blood flow confirms death when application of minimum clinical criteria (as defined in Recommendation A.1) cannot be completed, or if the interpretation of clinical criteria is confounded. There are currently no satisfactory ancillary tests for confirmation of neurologically determined death in instances of isolated primary brain stem injury.

**Recommendation A.8: Physicians declaring neurological death**

We recommend that the minimum level of physician qualification required to perform NDD be

- Full and current licensure for independent medical practice in the relevant Canadian jurisdiction
- Skill and knowledge in the management of patients with severe brain injury and in NDD.

In cases of NDD for purposes of postmortem donation, we recommend that any physician who has had any association with the proposed recipient that might influence the physician’s judgment shall not take any part in the declaration of death.

**Key considerations**

- For the purposes of this recommendation, a physician with “full and current licensure for independent practice in the relevant Canadian jurisdiction”
  - is any physician licensed by the college of physicians and surgeons or licensing authority in that jurisdiction.
  - excludes physicians who are only on an educational register.
  - does not require a particular level of specialty certification; nonspecialists can declare NDD if they have the requisite skill and knowledge.
- The authority to perform NDD cannot be delegated.

**Recommendation A.9: Age-related criteria**

We recommend that recommendations A.1 to A.8 for NDD be applied to infants, children and adolescents, with the following qualifications.

**NDD recommendations specific to children and adolescents**

- For all children ≥ 1 year (corrected for gestational age), NDD standards established at the forum should apply. A second physician performing the NDD is required by law for the purposes of postmortem transplantation, with no fixed interval of time required, regardless of the primary mechanism of the brain injury (see Recommendation A.5).
- The minimum level of physician qualifications should be understood as specialists with skill and knowledge in the management of children and/or adolescents with severe brain injury and NDD (see Recommendation A.8).

**NDD recommendations specific to infants and children aged 30 days to 1 year (corrected for gestational age)**

- The minimum clinical criteria include the oculocephalic reflex, as this test may be more reliable than the vestibulo-ocular reflex in infants due to the unique anatomy of the external auditory canal (see Recommendation A.1).
- A repeat examination at a different time is recommended to ensure independent confirmation by another qualified physician, regardless of the primary mechanism of the brain injury. It is prudent to have an independent examination because of the lack of collective experience and research on brain death in this age group. There is no recommended minimum time interval between determinations. Should uncertainty or confounding issues arise that cannot be resolved, the time interval may be extended according to physician judgment, or an ancillary test demonstrating absence of intracerebral blood flow may be used.
- The minimum level of physician qualifications should be understood as specialists with skill and knowledge in the management of infants with severe brain injury and NDD (see Recommendation A.8).

**Key considerations**

- Studies should be undertaken to evaluate the necessity of this second examination relative to the risks (e.g., of repeating the apnea test, time delays with an impact on family stress and donor stability).
- Recommendations on NDD in newborns < 30 days were addressed in a separate forum.

**Neonatal recommendations**

The Neonatal Reference Group recommends that all NDD standards established at the forum be adopted with the following adjustments and emphases:

**NDD recommendations for term newborns aged < 30 days**

- Standards apply to newborns aged > 36 weeks’ gestation at the time of death.
- NDD is a clinical diagnosis, i.e., clinical criteria have primacy.
- Minimum clinical criteria include absence of oculocephalic reflex and suck reflex.
- Minimum temperature must be a core temperature ≥ 36°C.
- Minimum time from birth to first determination is 48 h.
- Two determinations are required, with a minimum interval of 24 h between examinations.
- Ancillary testing, as defined by demonstration of the absence of intracerebral blood flow, should be performed when any of the minimum clinical criteria cannot be established or confounding factors remain unresolved.
- “Minimum level of physician qualifications” should be understood as specialists with skill and knowledge in the management of newborns with brain injury and the determination of death based on neurological criteria.
Key considerations
• Accuracy of gestational age should be supported by clinical history (e.g., dates and prenatal ultrasound) and physical examination. Inability to confirm a gestational age > 36 weeks should preclude NDD.
• The higher recommended temperature thresholds reflect uncertainty about hypothermic effects on neurological function in the newborn and the fact that normothermia is an easily attainable standard.
• The 48-h recommendation from injury to first determination reflects a reduced certainty of neurological prognostication before the first 48 h of life.
• Prospective research should be done to confirm the necessity of the recommended 24-h interval between determinations.

B. Representation of NDD: incidence, reporting and legal issues

Recommendation B.1: Legal timing of death
We recommend that the legal time of death be marked by the first determination of death.

Recommendation B.2: Reporting
We recommend that NDD be reported when determined.

Key consideration
Currently, there are no mechanisms to report the incidence of NDD in Canada. Given that NDD is a prerequisite for cadaveric organ donation, there is a need to record this information for use in the analysis of statistics on organ donation.

Recommendation B.3: Reporting mechanisms
We recommend that the mechanism for reporting NDD be through the medical certificate of death and that hospitals be responsible for directing completed information to the appropriate agencies, such as the Canadian Institute for Health Information.

Key considerations
• Physicians should be required to report NDD through a single mechanism.
• Specific provisions for reporting NDD should be included on the medical certificate of death. If the NDD portion of the certificate is not completed, it should be returned to the physician for completion.

Recommendation B.4: Legal issues
We recommend that Canadian medical requirements for NDD (determined at this forum) be embodied in medical standards and clinical practice guidelines.

Key consideration
Hospital practices related to NDD vary across the country.

There is a need to align them (e.g., accreditation) with medical standards and clinical practice guidelines related to NDD.

C. Severe brain injury: from emergency department to ICU

Recommendation C.1: Recognition of NDD
We recommend that all patients who are suspected of being brain dead be assessed for NDD unless this has no implications for prognostication or management, including end-of-life care (see Recommendation C.3).

Recommendation C.2: Emergency department to ICU triage — evolving neuroprotective therapies
We recommend that all patients with severe brain injury who may benefit from treatment, prognostication or optimal end-of-life care within an ICU have access to these services.

Key considerations
• Patient and family wishes must be considered, e.g., wishes made known during clinician consultations, in advance directives, on organ donor cards and to an organ donor registry.
• ICU is defined as care provided in an ICU, not critical care offered in an emergency department.
• Access to ICU services for patients with severe brain injury should be in addition to preserving access to ICU for other critically ill patients.
• Resource and societal issues require consideration.
• Clinicians need to have some flexibility in decision-making.

Recommendation C.3: End-of-life care
We recommend that for patients who die as a result of severe brain injury, standard postmortem care should include the option of organ and tissue donation for eligible patients.

This article has been peer reviewed.
Surgeons of British Columbia (Seland), Canadian Association of Emergency Physicians (Cass), Canadian Association of Critical Care Nurses (Jefferson), Canadian Association of Transplantation (Young), Canadian Neurocritical Care Group (Teitelbaum).

See Appendix 1 for a complete list of forum participants.

Competing interests: None declared.

Acknowledgements: These recommendations have been endorsed by the Canadian Critical Care Society, Canadian Association of Emergency Physicians, Canadian Neurological Society, Canadian Neurocritical Care Group (recommendations A and B), Canadian Neurocritical Care Group, Conference of Chief Coroners and Medical Examiners of Canada, Canadian Association of Critical Care Nurses, Canadian Association of Transplantation, Canadian Society of Transplantation, Quebec Transplant, Trillium Gift of Life Network and its ICU Advisory Group, Alberta HOPE Programs, Newfoundland OPEN Program, Transplant Atlantic, New Brunswick Transplant and the Canadian Council for Donation and Transplantation.

The authors wish to acknowledge the financial support of the Canadian Council for Donation and Transplantation and the process consultation provided by Strachan-Tomlinson and Associates.

REFERENCES

1. Wijdicks EF. Brain death worldwide: accepted fact but no global consensus in diagnostic criteria. Neurology 2002;58(1):20-5.
2. Shemie SD. Variability of brain death practices. Crit Care Med 2004;32(12):2574-5.
3. Powner DJ, Hernandez M, Rives TE. Variability among hospital policies for determining brain death in adults. Crit Care Med 2004;32(6):1284-8.
4. Mejia RE, Pollack MM. Variability in brain death determination practices in children. JAMA 1995;274(7):559-3.
5. Chang MY, McBride LA, Ferguson MA. Variability in brain death declaration practices in pediatric head trauma patients. Pediatr Neurosurg 2003;39(1):7-9.
6. Canadian Congress Committee on Brain Death. Death and brain death: a new formulation for Canadian medicine. CMAJ 1998;158(5):405-6.
7. Canadian Neurocritical Care Group. Guidelines for the diagnosis of brain death. Can J Neurol Sci 1999;26(1):64-6.
8. Quality Standards Subcommittee of the American Academy of Neurology. Practice parameters for determining brain death in adults [summary statement]. Neurology 1995;55(5):1012-24.
9. Burke K. Legal foundations for the neurological determination of death. Edmonton: Canadian Council for Donation and Transplantation; 2003.
10. Barron LB, Shemie SD, Doig C. A review of literature on the neurological determination of death. Edmonton: Canadian Council for Donation and Transplantation; 2003.
11. Hoenby RH, Shemie SD. Survey and analysis of hospital-based brain death guidelines in Canada. Edmonton: Canadian Council for Donation and Transplantation; 2003.
12. Decima Research. Survey of Canadian critical care and neuroscience physicians on severe brain injury, brain death and organ donation. Edmonton: Canadian Council for Donation and Transplantation; 2003.
13. Booth CM, Boone RH, Tomlinson G, et al. Is this patient dead, vegetative, or severely neurologically impaired? Assessing outcome for comatose survivors of cardiac arrest. JAMA 2004;291(7):870-9.
14. Lopez-Navidad A, Caballero F, Domingo P, et al. Early diagnosis of brain death in patients treated with central nervous system depressant drugs. Transplantation 2000;70(1):121-5.
15. Guidelines for the determination of death. Report of the medical consultants on the diagnosis of death to the President’s Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research. JAMA 1981;246(19):2484-6.
16. Wilkening M, Lowrier N, D’Athis P, et al. Validity of cerebral angiography via venous route in the diagnosis of brain death. Bull Acad Natl Med 1995;179(1):41-8. French.
17. Wieler H, Marohl K, Kaiser KP, et al. Tc-99m HMPAO cerebral scintigraphy. A reliable, noninvasive method for determination of brain death. Clin Nucl Med 1993;18(10):1049.
18. Spieth ME, Ansari AN, Kawada TK, et al. Direct comparison of Tc-99m DPTA and Tc-99m HMPAO for evaluating brain death. Clin Nucl Med 1994;19(10):857-72.
19. Bonetti MG, Ciritella P, Valle V, et al. 99mTc HM-PADO brain perfusion SPECT in brain death. Neuroradiology 1995;37(5):385-9.
20. Ducrocq X, Braun M, Dehouwer M, et al. Brain death and transcranial Doppler: experience in 130 cases of brain dead patients. J Neurosci Med 1998;80(1):41-6.
21. A definition of irreversible coma: report of the Ad Hoc Committee of the Harvard Medical School to Examine the Definition of Brain death. JAMA 1982;248(6):337-40.
22. Young GB, Shemie SD, Doig C, et al. The role of ancillary tests in the neurological determination of death. Can J Anaesth 2000; in press.

Correspondence to: Dr. Sam D. Shemie, Division of Pediatric Critical Care, Montreal Children’s Hospital, McGill University Health Centre, Montréal QC H3H 1P3; sam.shemie@muhc.mcgill.ca

Reprint requests to: Ms. Kimberly Young, Canadian Council for Donation and Transplantation, 1702-8215 112 St., Edmonton AB T6G 2C8; 780 409-5652; kimberly.young@ccdt.ca
Appendix 1: Forum participants

Pediatric Reference Group (PRG) and Neonatal Reference Group (NRG)

Dr. Natalie Anton (PRG and NRG), Pediatric Intensivist, Division of Pediatric Critical Care, Stollery Children’s Hospital, University of Alberta, Edmonton, Alta.; Dr. Keith Barrington (NRG), Canadian Critical Care Society, Chief of Neonatology, Royal Victoria Hospital, McGill University Health Centre, Montréal, Que.; Dr. Paul Byrne (PRG and NRG), Interim Director, John Dossetor Health Ethics Centre, Clinical Professor, Department of Pediatrics, University of Alberta, Clinical Director, Neonatal Intensive Care Unit, Stollery Children’s Hospital, Edmonton, Alta.; Dr. Catherine Farrell (PRG and NRG), Pediatric Intensivist, Département de Pédiatrie, Hôtel Sainte Justine, Associate Clinical Professor, University of Montreal, Montréal, Que., and Canadian Critical Care Society; Cecil Hahn (NRG), Division of Neurology, Boston Children's Hospital, Harvard University; Jonathan Hellmann (NRG), Division of Neonatology, Hospital for Sick Children, University of Toronto, Toronto, Ont.; Ms. Karen Hornby (PRG and NRG), Research Nurse Coordinator, Intensive Care Unit, Montreal Children’s Hospital, McGill University Health Centre, Montréal, Que., and Canadian Association of Critical Care Nurses; Dr. James Hutchison (PRG), Director of Education, Department of Critical Care Medicine, Hospital for Sick Children and Scientist, Hospital for Sick Children Research Institute, and Associate Professor, Faculty of Medicine, University of Toronto, Toronto, Ont.; Ms. Lisa McCarthy (PRG and NRG), Coordinator, Organ Donation Program, Department of Critical Care Medicine, Hospital for Sick Children, In-Hospital Organ Donation Coordinator, Trillium Gift of Life Network, Toronto, Ont., and Canadian Association of Transplantation and Canadian Association of Critical Care Nurses; Dr. Sam D. Shemie (forum chair, PRG and NRG), Pediatric Critical Care, Montreal Children’s Hospital, Associate Professor of Pediatrics, McGill University, Montréal, Que., and Honorary Staff, Department of Critical Care Medicine, Hospital for Sick Children, Associate Professor of Pediatrics, University of Toronto, Toronto, Ont.; Dr. Michael Shevell (PRG and NRG), Associate Professor, Departments of Neurology/Neurosurgery and Pediatrics, Associate Member, Department of Human Genetics, McGill University, Attending Physician, Division of Pediatric Neurology, Montreal Children’s Hospital, McGill University Health Centre, Montréal, Que., and President, Canadian Association of Child Neurology, Chair, Ethics Committee, Child Neurology Society, Member, Executive Board, International Child Neurology Association

Forum Recommendations Group

Dr. Andrew Baker, Medical Director, Trauma and Neurosurgery ICU, St. Michael’s Hospital, University of Toronto, Toronto, Ont., and Chair, Clinical Advisory Committee, Trillium Gift of Life Network and Canadian Critical Care Society and Canadian Anesthesiologists’ Society; Dr. Paul Byrne, Interim Director, John Dossetor Health Ethics Centre, University of Alberta, Clinical Director, Neonatal Intensive Care Unit, Stollery Children’s Hospital, Clinical Professor, Department of Pediatrics, University of Alberta, Edmonton, Alta.; Dr. Dan Cass, Chief of Emergency Medicine, St. Michael’s Hospital, University of Toronto, Toronto, Ont., Canadian Association of Emergency Physicians; Dr. Bernard Dickens, Professor, Faculty of Law, University of Toronto, Toronto, Ont.; Dr. Christopher Doig, Multisystems Intensive Care Unit, Foothills Hospital, Department of Critical Care, University of Calgary, Calgary, Alta., and Chair, Donation Committee and Canadian Council for Donation and Transplantation, and Canadian Critical Care Society; Dr. Cameron Guest, Chief Medical Officer, Trillium Gift of Life Network, Chief, Department of Critical Care Medicine, Sunnybrook and Women’s College Health Sciences Centre and Assistant Professor, Critical Care Medicine and Anaesthesia, University of Toronto, Toronto, Ont.; Ms. Rosella Jefferson, Intensive Care Unit, Children’s and Women’s Health Centre of BC, Vancouver, BC, and Member and Past President, Canadian Association of Critical Care Nurses; Dr. Graeme Rocker, Associate Professor of Medicine, Dalhousie University, Critical Care Program, Queen Elizabeth II Health Sciences Centre, Halifax, NS, and President, Canadian Critical Care Society; Dr. T. Peter Seland, Deputy Registrar (Ethics), College of Physicians and Surgeons of British Columbia, Vancouver, BC; Dr. Sam D. Shemie (forum chair), Pediatric Critical Care, Montreal Children’s Hospital, Associate Professor of Pediatrics, McGill University, Montréal, Que., and Honorary Staff, Department of Critical Care Medicine, Hospital for Sick Children, Associate Professor of Pediatrics, University of Toronto, Toronto, ON; Dr. Jeanne Teitelbaum, Associate Professor of Neurology and Critical Care, Montreal Neurological Institute and Hospital, McGill University, Associate Professor of Neurology and Critical Care, Maisonneuve-Rosemount Hospital, University of Montreal, Montréal, Que., and Canadian Neurological Society and President, Canadian Neurocritical Care Group and Co-author, Canadian Neurocritical Care Guidelines; Dr. Brian Wheelock, Division of Neurosurgery, Dalhousie University, Atlantic Health Sciences Corporation, Saint John, NB, and Past President, Canadian Neurosurgical Society; Ms. Kimberly Young, Senior Policy Analyst, Canadian Council for Donation and Transplantation Secretariat, Health Canada, Edmonton, Alta., and Forum project manager, Severe brain injury to neurological determination of death

Other forum participants

Mr. Abram Almeda, Executive Director, Acute and Tertiary, Nova Scotia Department of Health, Halifax, NS; Dr. Simon Avis, Chair, Conference of Chief Coroners and Chief Medical Examiners of Canada, Province of Newfoundland and Labrador, Health Sciences Centre, Saint John’s, Nfld.; Dr. Len Baron, Clinical Lecturer, Department of Anesthesia, University of Alberta, Edmonton, Alta.; Mr. Bill Barrassle, Provincial Executive Director, British Columbia Transplant Society, Vancouver, BC; Mr. David Baxter, Executive Director, Urban Futures Institute, Vancouver, BC; Dr. François Bélanger, Canadian Association of Emergency Physicians, President, Canadian Association of Emergency Physicians; Dr. Philip Belltsky, Director, Transplantation Services, Queen Elizabeth II Health Sciences Centre, Halifax, NS, and Chair, Canadian Council for Donation and Transplantation; Mr. Max Bishop, Provincial Coordinator, Organ Donor Program, Health Care Corp., Saint John’s, Nfld.; Dr. Darrell Boone, General Surgery, Trauma and Critical Care Medicine, Health Sciences Centre, Memorial University of Newfoundland, Saint John’s, Nfld. and Canadian Critical Care Society; Dr. Ross Brown, Trauma Surgeon, Trauma Services, Vancouver, BC, and Trauma Association of Canada; Ms. Sonya Canzian, Canadian Association of Neurosciences Nurses, Neurosurgery and Trauma ICU, St. Michael’s Hospital, Toronto, Ont.; Dr. Jean-Louis Caron, Neurosurgeon, Canadian Neurosurgical Society; Dr. Lawrence Klein, Medical Director, Palliative Care Services and Canadian Hospice Palliative Care Association, Ottawa, Ont.; Mr. Mme Mané Cléroux, Executive Director, Québec-Transplant, Montréal, Que., and Canadian Association for Transplantation; Dr. Réal Cloutier, Inspecteur-Enquêteur, Secrétariat comité transplant, Collège des Médecins du Québec, Montréal, Que.; Dr. Louise Dion, Senior Medical Officer, Canadian Medical Protective Association, Ottawa, Ont.; Dr. Peter Dodek, Physician Operations Leader, ICU, St. Paul’s Hospital, Vancouver, BC, and Canadian Critical Care Society; Dr. Graeme Dowling, Chief Medical Examiner for Alberta, Medical Examiner’s Office, Edmonton, Alta.; Dr. Chris Ekg, Neurosurgeon, Canadian Neurosurgical Society; Mr. Raffaele Forcione, Organ Donation Coordinator, continued on next page
Québec-Transplant, Montréal, Que.; Dr. Richard Fox, Neurosurgeon, University of Alberta, Edmonton, Alta., Canadian Neurosurgical Society; Ms. Susan Fox, Senior Analyst, Canadian Council for Donation and Transplantation, Edmonton, Alta.; Ms. Lori Garchinski, President, Canadian Association of Critical Care Nurses; Ms. Liz Anne Gilham-Eisen, Unit Manager, Cells, Tissues and Organs, Policy and Promotion Division, Biologics and Genetic Therapies Directorate, Health Canada, Ottawa, Ont.; Mr. Clay Gillrie, BOD/Provincial Director, Emergency Nurses Group of British Columbia and National Emergency Nurses Affiliation; Dr. Peter Glynn, Health Care Consultant, Kingston, Ont.; Dr. Robert Gordon, Manager, Multi-Organ Transplant Program, London Health Sciences Centre, London, Ont.; Dr. Peter Gorman, Canadian Neurosurgical Society, Neurosurgeon, The Moncton Hospital, Moncton, NB; Ms. Lisa Goulet, Advanced Nurse Practitioners, Nurse Clinician, Organ and Tissue Donation, McGill University Health Center, Montréal, Que.; Dr. Tim Graham, Emergency Physician, University of Alberta Hospital, Edmonton, Alta. and Canadian Association of Emergency Physicians; Ms. Nora Hammell, Director of Nursing Policy, Canadian Nurses Association, Ottawa, Ont.; Dr. David Hollomby, Richard Ivey Professor and Chair, Department of Medicine, University of Western Ontario, London, Ont.; Dr. Chris Honey, Canadian Neurosurgical Society, Neurosurgeon; Dr. Draga Jichici, Canadian Neurological Society and Assistant Professor of Medicine, Department of Critical Care Medicine and Neurosurgery, McMaster University, Hamilton, Ont.; Mr. David Johnson, Canadian Neurosurgical Society, Division of Critical Care Medicine, University of Alberta, Edmonton, Alta.; Ms. Nora Johnston, Project Team Leader, Population Health Strategies Branch, Alberta Health & Wellness, Edmonton, Alta.; Ms. Catherine Jones, Trauma Coordinators of Canada, Trauma Manager for Northshore Coast Garabaldi Region of Vancouver, Lions Gate Hospital, Vancouver, BC; Dr. Darvin Kealey, President and Chief Executive Officer, Trillium Gift of Life Network, Toronto, Ont.; Dr. Suneel Khetarpal, Assistant Professor of Surgery McGill University, The Montreal General Hospital, Montréal, Que., and Trauma Association of Canada; Dr. Stephan Langevin, Anesthesiologist, Intensivist, Department d’Anaesthesie, Hopital de L’Enfant-Jésus, Québec, Que., and Canadian Critical Care Society, and Quebec Society of Intensivists; Dr. Donald H. Lee, Canadian Neurological Society, Neuroradiologist, London Health Sciences Centre, London, Ont.; Ms. Grace MacConnell, Board Member and Canadian Association of Critical Care Nurses; Mrs. Heather MacDonald, Clinical Nurse Specialist, Critical Care and Queen Elizabeth II Health Sciences Centre, Halifax, NS, and Canadian Association of Transplantation; Mr. Neil MacDonald, Director, Alberta Health and Wellness, Edmonton, Alta.; Mrs. Caroline McCarr-Berry, Emergency Nurse, Queen Elizabeth II Health Sciences Centre, Halifax, NS, Flight Nurse, EHS LifeFlight and National Emergency Nurses Affiliation; Mrs. Florence Miller, Medical/Surgical/Neuro ICU Nurse, Queen Elizabeth II Health Sciences Centre, Halifax, NS, and Canadian Association of Neuroscience Nurses; Dr. Rick Moulton, Canadian Neuroscience Society, Neurosurgeon, St. Michael’s Hospital, Toronto, Ont.; Ms. Dawnelda Murray, Critical Care Donor Coordinator, Capital Health, Queen Elizabeth II Health Sciences Centre, Halifax, NS; Dr. Joe Pagliarelli, Medical Director, Adult Critical Care, Organ and Tissue Donation Program, The Ottawa Hospital, Ottawa, Ont., and Canadian Critical Care Society; Dr. Merril A. Pauls, Physician, The College of Family Physicians of Canada; Ms. Jeanette Pearce, Trauma Coordinators of Canada, Regional Pediatric Trauma Coordinator, Alberta Children's Hospital, Calgary, Alta.; Dr. Daryl Pullman, Canadian Bioethics Society, Associate Professor of Medical Ethics, Memorial University of Newfoundland, Saint John’s, Nfld.; Dr. Roy Purserell, Head, Department of Emergency Medicine, Vancouver General Hospital, University of British Columbia, Vancouver, BC, and Canadian Association of Emergency Physicians; Dr. Donna Radmanovich, Medical Care Consultant, Alberta Health & Wellness, Edmonton, Alta.; Dr. Kesava Reddy, McMaster University, Hamilton, Ont. and Canadian Neurosurgical Society; Ms. Darlene Schindel, Neurosurgical Nurse Coordinator, Canadian Association Neurosurgery Nurses; Dr. Peter Seland, Deputy Registrar (Ethics), College of Physicians & Surgeons of British Columbia, Vancouver, BC; Dr. Michael Sharpe, Associate Professor, Department of Anesthesia, London Health Sciences Center, London, Ont. and Canadian Society of Transplantation and and Canadian Critical Care Society; Mrs. Heather Stoyles, Medical/Surgical/Neuro ICU Nurse, Canadian Association of Neuroscience Nurses; Mr. Michael Strofolino, President, 50 Excel and Past President & CEO, The Hospital for Sick Children; Ms. Jennifer Thomas, Deputy Editor (Scientific), Canadian Medical Association Journal, Ottawa, Ont.; Ms. Frantise Verville, RN-Transplant Coordinator, National Emergency Nurses Affiliation; Mr. Joseph Volpe, Member of Parliament for Eglinton-Lawrence and Former Chair, Standing Committee on Health for the report Organ and Tissue Donation and Transplantation: A Canadian Approach; Dr. Ian Walker, Canadian Association of Emergency Physicians, Staff Physician, Calgary Regional Department of Emergency Medicine, Calgary, Alta.; Mr. Greg Webster, Canadian Organ Replacement Registry, Manager, Clinical Registries, Canadian Institute for Health Information (CIHI), Ottawa, Ont.; Dr. Kim Wiebe, Canadian Critical Care Society and Assistant Professor, Department of Internal Medicine, University of Manitoba, Winnipeg, Man.; Dr. Eelco F. Wijdicks, Medical Director, Neurology-Neurosurgery ICU, Professor of Neurology, Mayo Medical School, Rochester, Minn.; Dr. Gordon Wood, Canadian Critical Care Society and Intensivist, Victoria General Hospital, Victoria, BC; Dr. Barrie Woodhurst, Canadian Neurosurgical Society and Neurosurgeon, Vancouver General Hospital, Vancouver, BC; Ms. Maggie Wylie, Director, Canadian Council for Donation and Transplantation, Edmonton, Alta.; Dr. Bryan Young, Canadian Neurological Society, Professor of Neurology, Former Chair, Neurocritical Care Group, University of Toronto, Toronto, Ont.; Ms. Bonnie Zabirka, Trauma Coordinators of Canada, Trauma Coordinator, Thunder Bay Regional Hospital, Thunder Bay, Ont.

Consultants
Strachan-Tomlinson and Associates; Research: Paul Tomlinson; Facilitation: Dorothy Strachan; Project Management: Peter Ashley
Appendix 2: Key terms

Brain death

- Brain death is ubiquitous in medical, nursing and lay literature. It is based on the concept of complete and irreversible loss of brain function. The Canadian Neurocritical Care guidelines\(^7\) define brain death as “the irreversible loss of the capacity for consciousness combined with the irreversible loss of all brainstem functions, including the capacity to breathe. Brain death is equivalent to death of the individual, even though the heart continues to beat and spinal cord functions may persist.” This was adopted as the definition of neurologically determined death by the forum members (see Recommendation A.7). The President’s Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research (USA)\(^{15}\) defines brain death as “irreversible cessation of all functions of the entire brain, including the brainstem. The clinical diagnosis of brain death is equivalent to irreversible loss of all brainstem function.”

- Although brain death is an accepted concept, the definition lacks clarity in the Canadian context. Distinctions between brainstem death (United Kingdom definition) and whole brain death (United States definition) are unclear in Canada.

- The actual process for determining brain death in Canada is legally stated as “according to accepted medical practice.” A purpose of this forum was to clearly define and standardize “accepted medical practice.”

Neurologic death

- A term that is similar to brain death, but not commonly used.

Neurological determination of death (NDD)

- NDD is the process and procedure for determining death of an individual. NDD (see Recommendation A.7) is not a new definition of death. It is intended to be the end result of a clear and standardized process for the determination of death based on neurologic or brain-based criteria. For the purposes of this forum, the term “brain death” was replaced by NDD.

Appendix 3: Ancillary testing

The demonstration of the absence of intracerebral blood flow is considered the standard as an ancillary test for NDD. Currently validated imaging techniques are cerebral angiography\(^{16}\) and radionuclide angiography.\(^{17}\) We recognize that additional cerebral blood flow imaging technologies may further develop or evolve, but they cannot be recommended at this time. Electroencephalograms are no longer recommended as an ancillary test, in view of limitations, as discussed below.

Recommended ancillary tests

**Cerebral angiography**

A selective radiocontrast 4-vessel angiogram visualizing both the anterior and posterior cerebral circulation should be obtained. Cerebral-circulatory arrest occurs when intracerebral pressure exceeds arterial inflow pressure. External carotid circulation should be evident and filling of the superior sinuses may be present. Angiography requires technical expertise and is performed in the radiology department; necessitating transport of a potentially unstable patient. Arterial puncture and catheter-related complications have been described. Radiocontrast can produce idiosyncratic reactions and end-organ damage, such as renal dysfunction.

**Radionuclide imaging techniques**

Radionuclide angiography (perfusion scintigraphy) for brain death confirmation has been widely accepted for a number of years. In the last decade, radiopharmaceuticals, especially Tc\(^{99m}\) hexamethylpropylene-amine oxime (Tc\(^{99m}\) HMPAO), have been studied extensively and provide enhanced detection of intracerebral, posterior fossa and brainstem blood flow.\(^{17,18}\) Tc\(^{99m}\) HMPAO is lipid-soluble, crossing the blood-brain barrier, providing information on arterial cerebral blood flow and uptake of tracer within perfused brain tissue. The traditional gamma cameras used in this technique are immobile, necessitating patient transfer for study; but newer technologies are portable, allowing for studies to be performed at the bedside.

**Ancillary tests in evolution***

**Transcranial Doppler ultrasonography**

Using a pulse Doppler instrument, the intracerebral arteries, including the vertebral or basilar arteries, are insonated bilaterally. Brain-dead patients display either absent or reversed diastolic flow or small systolic spikes.\(^{20}\) The noninvasiveness and portability of this technique are advantageous, but the technology requires substantial clinical expertise for proper application and is not widely available. It has not been sufficiently validated at this time.

**Magnetic resonance imaging (MRI)**

MRI-based angiography and imaging hold future promise but are not easily available and have not been sufficiently validated at this time.

**Electroencephalography (EEG)**

EEG is readily available in most tertiary medical centres worldwide and has long been used as a supplementary test for brain death.\(^{21}\) It can be performed at the bedside, but has significant limitations.\(^{22}\) The EEG detects cortical electrical activity, but is unable to detect deep cerebral or brainstem function. The high sensitivity requirement for EEG recording may result in detection of electric interference from many of the devices that are commonplace in the ICU setting. EEG is also significantly affected by hypothermia, drug administration and metabolic disturbances, thus diminishing its clinical utility. It is no longer recommended as an ancillary test.

* The use of alternative ancillary tests, such as MR angiography or CT angiography, will be addressed in a follow-up forum scheduled for late 2006.
### Appendix 4: Checklists for neurological determination of death

#### Definitions and notes

- **Age definitions**: “Children” are those 1–18 years of age. “Infants” are 30 days to 1 year old (corrected for gestational age). “Term newborns” are 36 weeks, gestation to 29 days old (corrected for gestational age).

- **Overarching principles**: The legal time of death is marked by the first determination of death. Existing law states that for the purposes of postmortem donation, the fact of death shall be determined by 2 physicians. The physicians’ determinations may be performed concurrently. If performed at different times, a full clinical examination including the apnea test must be performed, without any fixed examination interval, regardless of the primary etiology.

For infants and term newborns, the first and second physicians’ determinations, as defined by a full clinical examination including the apnea test, must be performed at 2 different times. For infants, there is no fixed interval regardless of the primary etiology. For term newborns, the first examination should be delayed 48 h after birth and the interval should be ≥ 24 h, regardless of primary etiology.

- **Physicians declaring neurological death**: Minimum level of physician qualifications to perform NDD is full and current licensure for independent medical practice in the relevant Canadian jurisdiction. This excludes physicians who are only on an educational register. The authority to perform NDD cannot be delegated. Physicians should have skill and knowledge in both the management of patients with severe brain injury and in determination of neurological death in the relevant age group. For the purposes of postmortem donation, a physician who has had any association with the proposed transplant recipient that might influence the physician’s judgment shall not take part in the declaration of death.

- **Minimum clinical criteria**: Established etiology: Absence of clinical neurological function with a known, proximate cause that is irreversible. There must be definite clinical or neuroimaging evidence of an acute central nervous system (CNS) event that is consistent with the irreversible loss of neurological function. NDD may occur as a consequence of intracranial hypertension, primary direct brainstem injury or both.

Deep unresponsive coma: A lack of spontaneous movements and absence of movement originating in the CNS, such as cranial nerve function, CNS-mediated motor response to pain in any distribution, seizures, decorticate and decerebrate responses. Spinal reflexes, or motor responses confined to spinal distribution, may persist.

Confounding factors:

- Unresuscitated shock
- Hypothermia (core temperature < 34°C and < 36°C for newborns by central blood, rectal, or esophageal-gastric measurements)
- Severe metabolic disorders capable of causing a potentially reversible coma. If the primary etiology does not fully explain the clinical picture and if in the treating physician’s judgement the metabolic abnormality may play a role, it should be corrected or an ancillary test should be performed.
- Peripheral nerve or muscle dysfunction or neuromuscular blockade potentially accounting for unresponsiveness
- Clinically significant drug intoxications (e.g., alcohol, barbiturates, sedatives); therapeutic levels or therapeutic dosing of anticonvulsants, sedatives and analgesics does not preclude the diagnosis.

Specific to cardiac arrest: Neurological assessments may be unreliable in the acute postresuscitation phase after cardiorespiratory arrest. In cases of acute hypoxic-ischemic brain injury, clinical evaluation for NDD should be delayed for 24 h, or an ancillary test could be performed.

Examiners are cautioned to review confounding issues in the context of the primary etiology and examination. Clinical judgment is the deciding factor.

Apnea test: Optimal performance requires a period of preoxygenation followed by 100% O₂ delivered via the trachea upon disconnection from mechanical ventilation. The certifying physician must continuously observe the patient for respiratory effort. Thresholds at completion of the apnea test: PaCO₂ ≥ 60 mm Hg and ≥ 20 mm Hg above the pre-apnea test level and pH ≤ 7.28 as determined by arterial blood gases. Caution must be exercised in considering the validity in cases of chronic respiratory insufficiency or dependence on hypoxic respiratory drive.

Ancillary tests: Demonstration of the global absence of intracerebral blood flow is considered the standard for determination of death by ancillary testing. The following prerequisite conditions must be met before ancillary testing:

- Established etiology
- Deep unresponsive coma
- Absence of unresuscitated shock and hypothermia.

Currently validated techniques are 4-vessel cerebral angiogram or radionuclide cerebral blood flow imaging. EEG is no longer recommended. NDD can be confirmed by ancillary testing when minimum clinical criteria cannot be completed or confounding factors cannot be corrected.
Appendix 5: Checklist for adults and children 1 year and older

Minimum clinical criteria
a. Deep unresponsive coma with the following established etiology ________________________________

b. Confounding factors precluding the diagnosis? Yes ❑ No ❑

c. Temperature (core) ________

d. Brainstem reflexes:
   - Bilateral absence of motor responses (excluding spinal reflexes) Yes ❑ No ❑
   - Absent cough Yes ❑ No ❑
   - Absent gag Yes ❑ No ❑
   - Bilateral absence of corneal responses Yes ❑ No ❑
   - Bilateral absence of vestibulo-ocular responses Yes ❑ No ❑
   - Bilateral absence of pupillary response to light (pupils ≥ mid-size) Yes ❑ No ❑

e. Apnea
   - At completion of apnea test: pH _______ PaCO₂ _______ mm Hg
     PaCO₂ ≥ 20 mm Hg above the pre-apnea test level Yes ❑ No ❑

Ancillary tests
Ancillary tests, as defined by determination of the absence of intracerebral blood flow, should be performed when any of the minimum clinical criteria cannot be established or unresolved confounding factors exist.

Ancillary testing has been performed Yes ❑ No ❑
Date: ______________ Time: ______________

Absence of intracerebral blood flow has been demonstrated by
- Cerebral radiocontrast angiography ❑
- Radionuclide angiography ❑
- Other ___________________________

Declaration and documentation
The first and second physicians’ determinations may be performed concurrently. If performed at different times, a full clinical examination including the apnea test must be performed, without any fixed examination interval, regardless of the primary etiology.

This patient fulfills the criteria for neurological determination of death
Physician (print name): __________________________ Signature: ______________________________
Date: ______________ Time: ______________

Standard end-of-life care
Is this patient medically eligible for organ or tissue donation? Yes ❑ No ❑
Has the option for organ or tissue donation been offered? Yes ❑ No ❑
Has consent been obtained for donation? Yes ❑ No ❑
Appendix 6: Checklist for infants less than 1 year old and term newborns (36 weeks gestation)

Minimum clinical criteria
a. Deep unresponsive coma with the following established etiology

b. Confounding factors precluding the diagnosis?
   Yes ☐ No ☐

c. Temperature (core) ______

d. Brainstem reflexes:
   - Bilateral absence of motor responses (excluding spinal reflexes) Yes ☐ No ☐
   - Absent cough Yes ☐ No ☐
   - Absent gag Yes ☐ No ☐
   - Absent suck (newborn only) Yes ☐ No ☐ Not applicable ☐
   - Bilateral absence of corneal responses Yes ☐ No ☐
   - Bilateral absence of vestibulo-ocular responses Yes ☐ No ☐
   - Bilateral absence of pupillary response to light (pupils ≥ mid-size) Yes ☐ No ☐

e. Apnea
   - At completion of apnea test: pH ______ PaCO₂ ______ mm Hg
   - PaCO₂ ≥ 20 mm Hg above the pre-apnea test level Yes ☐ No ☐

Ancillary tests
Ancillary tests, as defined by determination of the absence of intracerebral blood flow, should be performed when any of the minimum clinical criteria cannot be established or unresolved confounding factors exist.

Ancillary testing has been performed Yes ☐ No ☐
Date: ______________ Time: ______________

Absence of intracerebral blood flow has been demonstrated by
- Cerebral radiocontrast angiography ☐
- Radionuclide angiography ☐
- Other ___________________

Examination interval, declaration and documentation
The first and second physicians’ determinations (a full clinical examination including the apnea test) should be performed at different times. For infants, there is no fixed examination interval. For newborns, the first examination should be delayed until 48 h after birth and the interval between examinations should be ≥ 24 h.

This patient fulfills the criteria for neurological determination of death
Physician (print name): __________________________ Signature: ______________________________
Date: ___________________ Time: ___________________

Standard end-of-life care
Is this patient medically eligible for organ or tissue donation? Yes ☐ No ☐
Has the option for organ or tissue donation been offered? Yes ☐ No ☐
Has consent been obtained for donation? Yes ☐ No ☐